Trial title	A trial to investigate the efficacy and safety of the combination encorafenib and binimetinib in Chinese participants with BRAF ^{V600E} lung cancer Multoriter Open kield, presel listudy with a safety kield in part investigating the efficacy, safety and premised chinese participants with metastatic normal cel Ling cancer who are EPVP and MEX emiliator treatment-naive	
Disease	Metastatic Non-Small cell lung cancer	
\bigcirc		
Treatment	Encorafenib (Braftovi®) in combination with Binimetinib (Mektovi®)	
Participants	Chinese participants with metastatic non-small cell lung cancer carrying a specific mutation in <i>BRAF</i> gene (<i>BRAF^{V600E}</i>)	
ĨĨĨĨ	Contying a specific matation in bitar gene (bitar)	
Trial dates	From 02 June 2022 (first participant first visit) to February 2025	
	(approximate End of trial)	
Trial Locations	China and Taiwan	
We do research to improve patient care. This trial will help us to answer important questions about treatment of metastatic lung cancer		



W00090GE203

Clinical Trial Protocol Lay Synopsis


This document is a brief summary of a clinical trial protocol. It is written in plain language for the general public, providing answers to the following questions:

- What is the purpose of the trial?
- What are the objectives of the trial and how are they evaluated?
- How is the trial conducted?
- Who can take part in the trial?
- What are the trial treatments and how are they administered?
- What are the possible benefits and risks in taking part in the trial?

What is the purpose of the trial?	At the time of the initiation of the OCEAN II trial, there was no therapy available in China for the treatment of patients with lung cancer targeting the specific genetic mutation called <i>BRAF</i> ^{VBODE} mutation.
	The combination of encorafenib and binimetinib is a marketed therapy (Braftovi [®] and Mektovi [®]) approved to treat patients with certain skin cancer (melanoma) in several countries (European Union, USA, Australia, Japan, Switzeland).
	Data of previous clinical studies have shown that the same type (BRAF and MEK inhibitors) is effective for lung cancer.
	This trial is a two-part trial to evaluate whether the combination of encorafenib and binimetinib is safe and effective in a specific group of metastatic <i>BRAF</i> ^{v600E} mutated lung cancer (non-small cell lung cancer) in Chinese participants.
What are the	The main objective of the first part of the trial is:
objectives of the trial and how are they evaluated?	• To investigate the safety (side effects) of encorafenib 450 mg and binimetinib 90 mg in Chinese participants with <i>BRAF^{V600E}</i> metastatic non-small cell lung cancer. This is measured with the number of participants with major unacceptable side effects during the first 28 days of treatment.
	The main objective of the second part of the trial is:
	 To see if the combination of encorafenib and binimetinib is effective in this type of lung cancer by counting the



W00090GE203	Clinical Trial Protocol Lay Synopsis	Pierre Fabre
	proportion of participants for whom the tun completely disappear after treatment (ove rate).	
	In addition, the trial allows:	
	 For the first and second parts, to describe the effects) of encorafenib and binimetinib or treatment enters the body, circulates in the and is finally eliminated with safety data number, frequency and type of side effects. For the second part, to further investigate the ecombination of encorafenib and binimetinib: 	and how the bloodstream including the
	 The time period the response to treatment (duration of response). 	is maintained
	 The time period between the treatment st tumor becomes worse (progression-free surv 	
	 The time period since the treatment start and death (overall survival). 	d participant's
How is the trial conducted?	A minimum of fifty-five (55) adult Chinese participant metastatic non-small cell lung cancer are in this ope	
	First part of the trial:	
	Nine (9) participants are in this first part and are encorafenib and binimetinib. After 28 days (one cycle for the first nine participants, an analysis is performe the safety of encorafenib and binimetinib.	e) of treatment
	If at least three (3) participants have a majo encorafenib and binimetinib are considered not saf is stopped.	
	If the treatment is sufficiently safe, the second part of	the trial starts.
	the trial	
	Forty-six (46) additional participants take part in the treated with encorafenib and binimetinib.	e trial and are
	If side effects are acceptable, all participants are encorafenib and binimetinib as long as they ber	





W00090GE203	Clinical Trial Protocol Lay Synopsis	re Fabre
	Participants are not pregnant, lactating or breast- women	feeding
What are the trial treatments and how are they administered ?	 Participants treated with the new therapy receive: 6 capsules of encorafenib once a day in the morn total daily dose of encorafenib is 450 mg 3 tablets of binimetinib twice a day (in the morning the evening). The total daily dose of binimetinib is 90 	g and in
What are the possible benefits and risks in taking part in the trial?	The combination of encorafenib and binimetinib is effective treat patients with certain melanoma and this type of tree (<i>BRAF and MEK</i> inhibitors) is effective to treat certain me lung cancer. Therefore, it is expected (but not guaranteed) that enco and binimetinib may have a beneficial effect on a participants with lung cancer and improve their disease. If so, other Chinese patients with the same disease may h opportunity to benefit from this treatment in the future. The trial may have potential discomforts and constraints participants requiring regular visits at hospital, blood so and imaging examinations.	eatment tastatic orafenib Chinese ave the s for the compling
	Encorafenib and binimetinib can cause side effects for participants are informed by trial doctors at study entry of closely monitors for all the duration of the trial.	



W00090GE203	Clinical Trial Protocol Lay Synopsis
Cinical Trial identification	
Protocol Number	W00090GE203
Protocol	5.0 dated 18 May 2022
Full trial title	Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in <i>BRAF^{V600E}</i> mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve
Registry ID	ClinicalTrials.gov: NCT05195632
	<u> Ocean II - ClinicalTrials.gov</u>
Who sponsors this trial?	
Name and	Pierre Fabre Médicament
contact details of	Les Cauquillous
the sponsor	81500 Lavaur-France

W00090GE203



	Glossary		
BRAF inhibitor	A treatment/drug that blocks a protein called BRAF which helps control cell growth.		
BRAFV600E	All humans have a gene called <i>BRAF</i> . The <i>BRAF</i> gene makes a protein that helps control cell growth. In some patients with colorectal cancer, this gene mutates (V600E mutation) and makes the tumor grow faster.		
Disease Progression	Cancer that continues to grow or spread.		
Duration of response	Time period the response to treatment is maintained.		
MEK inhibitor	A treatment/drug that block a protein called MEK which helps control cell growth.		
Metastatic tumor	Metastasic means that cancer has spread to a different part of the body than where it started.		
Non-small cell lung cancer	A group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope.		
Open-label	A type of trial in which both the doctors and the participants are aware of the treatment being given.		
Overall response rate	The proportion of participants for whom the tumors shrink or completely disappear after treatment.		
Overall survival	Time period between the treatment start and participant's death.		
Progression free survival	Time period between the start of treatment and the disease worsens.		
Side effects	Side effects are unwanted medical events (such as headache) that happen during the trial and that are related or possibly related to trial treatment.		